Compugen Market Cap ($159.88 Million)
Market Cap & Net Worth: Compugen (CGEN)
Compugen market cap. Compugen (TA:CGEN) has a market capitalization of $159.88 Million (ILA59.64 Billion) as of November 1, 2026. Listed on the TA stock exchange, this Israel-based company holds position #17228 globally and #209 in its home market, demonstrating a 3.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Compugen's stock price ILA630.50 by its total outstanding shares 94584636 (94.58 Million). Also see CGEN operating cash flow for how efficiently the company converts equity into cash flow.
Compugen Market Cap History (2015–2026)
Compugen market cap history from 2015 to 2026. Data shows change from $620.00 Million to $159.88 Million (-11.12% CAGR). Check Compugen stock price for real-time trading data and today's change.
Compugen Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Compugen's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Compugen net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.65x
Compugen's market cap is 1.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.41x
Compugen's market cap is 3.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $498.03 Million | $712.00K | -$31.51 Million | 699.48x | N/A |
| 2018 | $214.55 Million | $17.80 Million | -$22.60 Million | 12.05x | N/A |
| 2020 | $988.95 Million | $2.00 Million | -$29.70 Million | 494.48x | N/A |
| 2021 | $339.54 Million | $6.00 Million | -$34.20 Million | 56.59x | N/A |
| 2022 | $61.39 Million | $7.50 Million | -$33.69 Million | 8.19x | N/A |
| 2023 | $174.46 Million | $33.46 Million | -$18.75 Million | 5.21x | N/A |
| 2024 | $142.76 Million | $27.86 Million | -$14.23 Million | 5.12x | N/A |
| 2025 | $120.40 Million | $72.76 Million | $35.34 Million | 1.65x | 3.41x |
Competitor Companies of CGEN by Market Capitalization
Companies near Compugen in the global market cap rankings as of November 1, 2026. Also see CGEN total assets for a full breakdown of the balance sheet.
Key companies related to Compugen by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Compugen (2015–2026)
Market capitalization of Compugen from 2015 to today. Between 2015 and today, Compugen's market cap moved from $620.00 Million to $ 159.88 Million, with a yearly change of -11.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA159.88 Million | +32.79% |
| 2025 | ILA120.40 Million | -15.67% |
| 2024 | ILA142.76 Million | -18.17% |
| 2023 | ILA174.46 Million | +184.18% |
| 2022 | ILA61.39 Million | -81.92% |
| 2021 | ILA339.54 Million | -65.67% |
| 2020 | ILA988.95 Million | +87.86% |
| 2019 | ILA526.43 Million | +145.36% |
| 2018 | ILA214.55 Million | -2.90% |
| 2017 | ILA220.97 Million | -55.63% |
| 2016 | ILA498.03 Million | -19.67% |
| 2015 | ILA620.00 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Compugen was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $159.88 Million USD |
| MoneyControl | $159.88 Million USD |
| MarketWatch | $159.88 Million USD |
| marketcap.company | $159.88 Million USD |
| Reuters | $159.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more